uniQure shares are trading lower after the company announced updated interim data on the Phase I/II clinical trials of AMT-130 for the treatment of Huntington's disease. Also, Mizuho downgraded the stock from Buy to Neutral and announced a $10 price target.
Benzinga Newsdesk - Dec 19, 2023, 12:47PM